Replies to post #254884 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

This technology (DCvax) is in the solid tumor market. Immediately that means it should be a nine multiple of the Car-T buyouts from a few years ago, but one has to take economies of scale, cap versus ceiling pressures etc. 23 billion is an inexpensive buyout for NWBO in short order if this trial is statistically significant.

Direct already has the science it needs to persuade big pharma of its potential -- if and when DCVax-L trial succeeds.